+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 33 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
R

Actively Recruiting

Researchers are evaluating the impact of adding locoregional treatments such as surgery and radiation, along with metastasis-targeted stereotactic body radiation therapy SBRT, to the usual HER2-targeted systemic therapy for patients with HER2-positive stage IV breast cancer that has spread to other parts of the body or to a limited number of sites oligometastatic. The study compares this multimodal approach to standard systemic therapy alone, aiming to assess overall survival and disease progression outcomes. This phase III trial includes patients whose cancers respond partially or completely to initial systemic therapy and also observes those with stable or progressing disease. Participants first receive standard HER2-targeted systemic treatments for 12 to 24 weeks, possibly including immunotherapy and chemotherapy drugs. Those with a positive response are randomized into two groups one group undergoes surgery and locoregional radiation therapy, followed by SBRT targeting metastatic lesions, then resumes systemic therapy the other group continues systemic therapy alone. Patients without a response continue systemic therapy in an observational cohort. Procedures such as breast conserving therapy or total mastectomy, radiation therapy with or without boost doses, and SBRT are delivered within specific timeframes post initial treatment. Throughout the study, participants undergo various imaging tests including echocardiography ECHO, MRI, mammography, ultrasound, CT, and PETCT scans, with optional biopsies and blood sample collections. Researchers monitor overall survival and progression-free survival for up to 10 years after treatment, with follow-up visits at regular intervals. The study also tracks treatment adherence, disease status, and side effects, aiming to understand the long-term effects of adding locoregional therapies to systemic treatment in this patient group.

Age: 18Years +All GendersPhase 3
59 locations
R

Actively Recruiting

Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.

Age: 18Years +All GendersPhase 2
53 locations
P

Actively Recruiting

Researchers are evaluating the use of carboplatin chemotherapy given before surgery in patients with high-risk prostate cancer who have inherited mutations in the BRCA1 or BRCA2 genes. This phase II trial aims to determine how well carboplatin works in shrinking tumors prior to surgery and to assess its impact on disease progression and survival. The study also monitors treatment side effects and collects tissue samples for future research. Participants receive carboplatin intravenously before undergoing prostate surgery. Those who show signs of disease progression after surgery will have imaging tests such as CT, MRI, chest X-ray, or PSMA PET scans. Blood samples are collected throughout the trial to monitor health and support additional studies. The study includes detailed follow-up to evaluate treatment outcomes and safety. During the trial, participants will have regular assessments including physical exams, PSA tests, and imaging scans if needed. Researchers will review the rate of complete tumor response after carboplatin treatment at surgery and track progression-free survival and overall survival over time. Safety and side effects of the treatment are closely monitored. Participation may last up to five years with ongoing collection of health data and specimens.

Age: 18Years +MALEPhase 2
133 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are studying muscle invasive bladder cancer to see if combining pembrolizumab, a type of immunotherapy, with radiation therapy after chemotherapy can help patients avoid bladder removal surgery. This phase II trial focuses on patients who have responded well to initial chemotherapy and aims to improve three-year bladder intact event-free survival. The study also evaluates survival rates, recurrence, and treatment side effects in participants. Participants receive photon beam radiation therapy once daily from Monday to Friday for up to 20 treatments. Pembrolizumab is given intravenously on the first day of each 21-day cycle, continuing for up to 18 cycles or about 12 months if there is no disease progression or unacceptable side effects. Before treatment, participants undergo a transurethral resection of bladder tumor TURBT and provide tissue samples. Imaging scans such as CT, MRI, or PET, along with cystoscopy and collection of urine and blood samples, are performed throughout the study. During the study, participants are closely monitored with regular assessments including imaging and questionnaires about symptoms. Follow-up visits occur every 26 weeks until two years after treatment and then annually up to five years. Researchers measure outcomes like bladder intact event-free survival, local recurrence, metastasis-free survival, overall survival, and rates of salvage cystectomy. Safety and treatment-related symptoms are tracked carefully, and specimens are collected for future research.

Age: 18Years +All GendersPhase 2
182 locations
P

Actively Recruiting

Researchers are evaluating treatment options for patients newly diagnosed with multiple myeloma who are considered frail or intermediate-fit and who are not candidates for stem cell transplant. This phase III trial compares three different three-drug induction regimens followed by either single or double drug maintenance therapies. The study aims to find which drug combination best controls the cancer and improves patient outcomes while considering patients age, other health conditions, and physical function. Participants are randomly assigned to one of three treatment arms. In Arm 1, patients receive bortezomib, lenalidomide, and dexamethasone with bortezomib given subcutaneously and the others taken orally for up to 9 cycles, followed by lenalidomide maintenance. Arm 2 involves daratumumab with hyaluronidase-fihj given subcutaneously, lenalidomide, and dexamethasone for induction, followed by lenalidomide maintenance. Arm 3 includes the same induction as Arm 2, but maintenance therapy combines daratumumab with hyaluronidase-fihj and lenalidomide. Each cycle lasts 28 days, and treatment continues without disease progression or unacceptable side effects. During the trial, participants undergo regular assessments including tumor measurements, blood tests, and quality-of-life questionnaires. Researchers monitor progression-free survival, overall survival, response rates, minimal residual disease status, and patient-reported symptoms and health status. After completing treatment, patients are followed up every 3 months for one year, every 6 months for two years, and then annually for up to 10 years to monitor long-term outcomes and safety.

All AgesAll GendersPhase 3
397 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations

1-10 of 33

1